These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9857976)

  • 1. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
    Smeraldi E; Zanardi R; Benedetti F; Di Bella D; Perez J; Catalano M
    Mol Psychiatry; 1998 Nov; 3(6):508-11. PubMed ID: 9857976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.
    Serretti A; Zanardi R; Rossini D; Cusin C; Lilli R; Smeraldi E
    Mol Psychiatry; 2001 Sep; 6(5):586-92. PubMed ID: 11526473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
    Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
    Mundo E; Guglielmo E; Bellodi L
    Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders.
    Yu YW; Tsai SJ; Chen TJ; Lin CH; Hong CJ
    Mol Psychiatry; 2002; 7(10):1115-9. PubMed ID: 12476327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene.
    Perna G; Favaron E; Di Bella D; Bussi R; Bellodi L
    Neuropsychopharmacology; 2005 Dec; 30(12):2230-5. PubMed ID: 16034444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.
    Zanardi R; Franchini L; Gasperini M; Lucca A; Smeraldi E; Perez J
    J Clin Psychopharmacol; 1998 Dec; 18(6):441-6. PubMed ID: 9864075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse.
    Weizman A; Weizman R
    Pharmacogenomics; 2000 Aug; 1(3):335-41. PubMed ID: 11256582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin transporter gene polymorphism and antidepressant response.
    Kim DK; Lim SW; Lee S; Sohn SE; Kim S; Hahn CG; Carroll BJ
    Neuroreport; 2000 Jan; 11(1):215-9. PubMed ID: 10683861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.
    Takahashi H; Yoshida K; Ito K; Sato K; Kamata M; Higuchi H; Shimizu T; Ito K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):477-81. PubMed ID: 12208565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.
    Yoshida K; Ito K; Sato K; Takahashi H; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):383-6. PubMed ID: 11817517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide.
    Mann JJ; Huang YY; Underwood MD; Kassir SA; Oppenheim S; Kelly TM; Dwork AJ; Arango V
    Arch Gen Psychiatry; 2000 Aug; 57(8):729-38. PubMed ID: 10920459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression.
    Benedetti F; Serretti A; Colombo C; Campori E; Barbini B; di Bella D; Smeraldi E
    Am J Psychiatry; 1999 Sep; 156(9):1450-2. PubMed ID: 10484962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
    Di Bella D; Erzegovesi S; Cavallini MC; Bellodi L
    Pharmacogenomics J; 2002; 2(3):176-81. PubMed ID: 12082589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interest of the use of pindolol in the treatment of depression: review].
    Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM
    Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET.
    Shioe K; Ichimiya T; Suhara T; Takano A; Sudo Y; Yasuno F; Hirano M; Shinohara M; Kagami M; Okubo Y; Nankai M; Kanba S
    Synapse; 2003 Jun; 48(4):184-8. PubMed ID: 12687637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
    Pollock BG; Ferrell RE; Mulsant BH; Mazumdar S; Miller M; Sweet RA; Davis S; Kirshner MA; Houck PR; Stack JA; Reynolds CF; Kupfer DJ
    Neuropsychopharmacology; 2000 Nov; 23(5):587-90. PubMed ID: 11027924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome.
    Rausch JL; Johnson ME; Fei YJ; Li JQ; Shendarkar N; Hobby HM; Ganapathy V; Leibach FH
    Biol Psychiatry; 2002 May; 51(9):723-32. PubMed ID: 11983186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.